|
Genmark Diagnostics Inc (GNMK) |
|
|
|
GNMK's Capital Expenditures Growth by Quarter and Year
Genmark Diagnostics Inc 's Capital Expenditures results by quarter and year
Select the Comparisons :
|
|
Select the Ratio:
|
Capital Expenditures Growth Y/Y▼
|
Capital Expenditures Growth Y/Y▼
|
GNMK Capital Expenditures (in millions $) |
FY 2020 |
FY 2019 |
FY 2018 |
FY 2017 |
IV Quarter |
December |
9.90
|
0.90
|
1.52
|
1.00
|
III Quarter |
September |
6.17
|
0.73
|
0.14
|
1.78
|
II Quarter |
June |
0.75
|
0.13
|
1.39
|
0.65
|
I Quarter |
March |
0.95
|
0.33
|
-0.47
|
1.89
|
FY |
|
17.77
|
2.09
|
2.58
|
5.32
|
GNMK Capital Expenditures fourth quarter 2020 Y/Y Growth Comment |
Genmark Diagnostics Inc achieved in the fourth quarter 2020, above Company average Capital Expenditures surge of 1000.22% year on year, to $ 9.90 millions.
Looking into fourth quarter 2020 results within Medical Equipment & Supplies industry 14 other companies have achieved higher Capital Expenditures growth. While Genmark Diagnostics Inc ' s Capital Expenditures doubling of 1000.22% ranks overall at the positon no. 101 in the fourth quarter 2020.
|
GNMK Capital Expenditures ( Y/Y Growth %) |
2020
|
2019 |
2018 |
2017 |
IV Quarter |
December |
1000.22 % |
-40.79 % |
52 % |
-61.54 % |
III Quarter |
September |
745.21 % |
421.43 % |
-92.13 % |
-34.07 % |
II Quarter |
June |
476.92 % |
-90.65 % |
113.85 % |
-54.86 % |
I Quarter |
March |
187.88 % |
- |
- |
6.78 % |
FY |
|
750.33 % |
-18.99 % |
-51.5 % |
-37.49 % |
GNMK Capital Expenditures (Quarter on Quarter Growth %) |
2020
|
2019 |
2018 |
2017 |
IV Quarter |
December |
60.49 % |
23.29 % |
985.71 % |
-43.82 % |
III Quarter |
September |
722.67 % |
461.54 % |
-89.93 % |
173.85 % |
II Quarter |
June |
-21.05 % |
-60.61 % |
- |
-65.61 % |
I Quarter |
March |
5.56 % |
-78.29 % |
- |
-27.31 % |
FY (Year on Year) |
|
750.33 % |
-18.99 % |
-51.5 % |
-37.49 % |
Capital Expenditures Y/Y Growth Statistics |
High |
Average |
Low |
1001.45 % |
134.75 % |
-92.36 % |
(Dec 31 2020) |
|
(Sep 30 2018) |
|
Capital Expenditures Y/Y Growth Statistics |
High |
Average |
Low |
1001.45 % |
134.75 % |
-92.36 % |
(Dec 31 2020) |
|
(Sep 30 2018) |
|
Capital Expenditures by Quarter for the Fiscal Years 2017, 2018, 2019, 2020 |
Genmark Diagnostics Inc 's Q/Q Capital Expenditures Growth
Capital Expenditures Q/Q Growth Statistics |
High |
Average |
Low |
1013.97 % |
77.88 % |
-100 % |
(Dec 31 2018) |
|
|
GNMK's IV. Quarter Q/Q Capital Expenditures Comment |
Genmark Diagnostics Inc achieved in the IV. Quarter 2020 below company average Capital Expenditures jump of 60.49% quarter on quarter, to $ 9.90 millions.
Albeit the IV. Quarter 2020 GNMK's Capital Expenditures sequential growth was below the average of 77.88 %, that was yet promising news, as the current improvement, transcends the 23.29% Capital Expenditures growth in the IV. Quarter a year ago
Within Medical Equipment & Supplies industry 47 other companies have achieved higher Capital Expenditures quarter on quarter growth. While Genmark Diagnostics Inc 's Capital Expenditures growth quarter on quarter, overall rank is 848. |
|
|
Capital Expenditures Q/Q Growth Statistics |
High |
Average |
Low |
1013.97 % |
77.88 % |
-100 % |
(Dec 31 2018) |
|
|
GNMK's IV. Quarter Q/Q Capital Expenditures Comment |
Genmark Diagnostics Inc achieved in the IV. Quarter 2020 below company average Capital Expenditures jump of 60.49% quarter on quarter, to $ 9.90 millions.
IV. Quarter 2020 GNMK's Capital Expenditures quarter on quarter growth were a mixed bag, although beneath the regular rise of 77.88 %, yet it shows absolute acceleration measured to the 23.29% in the same quarter a year ago Eleanora Ricci, Medical Equipment & Supplies industry expert from New York wrote.
Within Medical Equipment & Supplies industry 47 other companies have achieved higher Capital Expenditures quarter on quarter growth. While Genmark Diagnostics Inc 's Capital Expenditures growth quarter on quarter, overall rank is 848. |
|
Genmark Diagnostics Inc 's 12 Months Capital Expenditures Growth Year on Year
Capital Expenditures TTM Growth |
12 Months Ending (Dec 31 2020) |
12 Months Ending (Sep 30 2020) |
12 Months Ending (Jun 30 2020) |
12 Months Ending (Mar 31 2020) |
12 Months Ending (Dec 31 2019) |
Cumulative Capital Expenditures 12 Months Ending |
$ 17.78 |
$ 8.77 |
$ 3.33 |
$ 2.71 |
$ 2.09 |
Y / Y Capital Expenditures Growth (TTM) |
749.71 % |
223.97 % |
57.13 % |
-19.63 % |
-18.76 % |
Year on Year Capital Expenditures Growth Overall
Ranking |
# 1694 |
# 132 |
# 562 |
# 511 |
# 2070 |
Seqeuential Capital Expenditures Change (TTM) |
102.62 % |
163.61 % |
22.76 % |
29.59 % |
-22.75 % |
Seq. Capital Expenditures Growth (TTM) Overall
Ranking |
# 1818 |
# 64 |
# 94 |
# 35 |
# 2604 |
Cumulative Capital Expenditures growth
Comment |
With 749.71% annual Capital Expenditures growth, Genmark Diagnostics Inc would report a record annual Capital Expenditures surge if the fiscal year would end on Dec 31 2020.
In the Healthcare sector 292 other companies have achieved higher trailing twelve month Capital Expenditures growth. While Capital Expenditures growth total ranking has deteriorated compare to previous quarter from 132 to 1694. |
Capital Expenditures TTM Q/Q Growth Statistics |
High |
Average |
Low |
749.71 % |
36.2 % |
-70.21 % |
|
|
|
|
|
Capital Expenditures TTM Y/Y Growth Statistics |
High |
Average |
Low |
749.71 % |
36.2 % |
-70.21 % |
|
|
|
Capital Expenditures TTM Q/Q Growth Company Ranking |
Within: |
No. |
Industry |
# 73 |
Sector |
# 302 |
S&P 500 |
# 1818 |
|
Cumulative Capital Expenditures growth
Comment |
With 749.71% annual Capital Expenditures growth, Genmark Diagnostics Inc would report a record annual Capital Expenditures surge if the fiscal year would end on Dec 31 2020.
In the Healthcare sector 292 other companies have achieved higher trailing twelve month Capital Expenditures growth. While Capital Expenditures growth total ranking has deteriorated compare to previous quarter from 132 to 1694. |
Capital Expenditures TTM Q/Q Growth Statistics |
High |
Average |
Low |
749.71 % |
36.2 % |
-70.21 % |
|
|
|
Capital Expenditures TTM Y/Y Growth Statistics |
High |
Average |
Low |
749.71 % |
36.2 % |
-70.21 % |
|
|
|
Capital Expenditures TTM Q/Q Growth Company Ranking |
Within: |
No. |
Industry |
# 73 |
Sector |
# 302 |
S&P 500 |
# 1818 |
Companies with similar Capital Expenditures surge for the quarter ending Dec 31 2020 within Healthcare Sector | Y/Y Change % | Capital Expenditures for the quarter ending Dec 31 2020 | Armata Pharmaceuticals Inc | 1,642.86% | $ 1,642.857 millions | T2 Biosystems Inc | 1,357.69% | $ 1,357.692 millions | Vanda Pharmaceuticals Inc | 1,320.59% | $ 1,320.588 millions | Beyond Air Inc | 1,225.33% | $ 1,225.333 millions | Co diagnostics Inc | 1,194.08% | $ 1,194.075 millions | Hepion Pharmaceuticals inc | 1,148.10% | $ 1,148.100 millions | Sinovac Biotech Ltd | 1,101.07% | $ 1,101.073 millions | Interpace Biosciences Inc | 1,053.85% | $ 1,053.846 millions | Reshape Lifesciences Inc | 1,042.86% | $ 1,042.857 millions | F star Therapeutics Inc | 1,034.38% | $ 1,034.375 millions | Igm Biosciences Inc | 1,018.00% | $ 1,018.000 millions | Genmark Diagnostics Inc | 1,001.45% | $ 1,001.446 millions | Frequency Therapeutics Inc | 949.41% | $ 949.406 millions | Cue Biopharma Inc | 945.68% | $ 945.678 millions | Nemaura Medical Inc | 923.56% | $ 923.560 millions | Evofem Biosciences Inc | 907.80% | $ 907.801 millions | Protalix Biotherapeutics inc | 882.14% | $ 882.143 millions | Acadia Pharmaceuticals Inc | 865.70% | $ 865.700 millions | Genocea Biosciences Inc | 839.04% | $ 839.041 millions | Pulmatrix Inc | 822.22% | $ 822.222 millions | Ocugen Inc | 817.99% | $ 817.992 millions | Constellation Pharmaceuticals Inc | 768.75% | $ 768.750 millions | Chinook Therapeutics Inc | 767.53% | $ 767.532 millions | Alpha Pro Tech Ltd | 759.85% | $ 759.848 millions | Sonoma Pharmaceuticals Inc | 755.56% | $ 755.556 millions | Volitionrx Limited | 731.08% | $ 731.079 millions | Cormedix Inc | 717.53% | $ 717.531 millions | Zynex inc | 707.14% | $ 707.143 millions | Odonate Therapeutics Inc | 700.00% | $ 700.000 millions | Arcus Biosciences Inc | 675.00% | $ 675.000 millions |
|